Crystal Structure and Characterization of Human Heavy-Chain Only Antibodies Reveals a Novel, Stable Dimeric Structure Similar to Monoclonal Antibodies

We report the novel crystal structure and characterization of symmetrical, homodimeric humanized heavy-chain-only antibodies or dimers (HC2s). HC2s were found to be significantly coexpressed and secreted along with mAbs from transient CHO HC/LC cotransfection, resulting in an unacceptable mAb develo...

Full description

Bibliographic Details
Main Authors: Carl Mieczkowski, Soheila Bahmanjah, Yao Yu, Jeanne Baker, Gopalan Raghunathan, Daniela Tomazela, Mark Hsieh, Mark McCoy, Corey Strickland, Laurence Fayadat-Dilman
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Antibodies
Subjects:
Online Access:https://www.mdpi.com/2073-4468/9/4/66
id doaj-1e33758d71ef4c78a8ebb00f37191035
record_format Article
spelling doaj-1e33758d71ef4c78a8ebb00f371910352020-11-25T04:11:29ZengMDPI AGAntibodies2073-44682020-11-019666610.3390/antib9040066Crystal Structure and Characterization of Human Heavy-Chain Only Antibodies Reveals a Novel, Stable Dimeric Structure Similar to Monoclonal AntibodiesCarl Mieczkowski0Soheila Bahmanjah1Yao Yu2Jeanne Baker3Gopalan Raghunathan4Daniela Tomazela5Mark Hsieh6Mark McCoy7Corey Strickland8Laurence Fayadat-Dilman9Discovery Biologics, Protein Sciences, Merck & Co., Inc., South San Francisco, CA 94080, USADepartment of Chemistry, Modeling and Informatics, Merck & Co., Inc., Kenilworth, NJ 07033, USADiscovery Biologics, Protein Sciences, Merck & Co., Inc., South San Francisco, CA 94080, USADiscovery Biologics, Protein Sciences, Merck & Co., Inc., South San Francisco, CA 94080, USADiscovery Biologics, Protein Sciences, Merck & Co., Inc., South San Francisco, CA 94080, USADiscovery Biologics, Protein Sciences, Merck & Co., Inc., South San Francisco, CA 94080, USADiscovery Biologics, Protein Sciences, Merck & Co., Inc., South San Francisco, CA 94080, USADepartment of Pharmacology, Mass Spectrometry & Biophysics, Merck & Co., Inc., Kenilworth, NJ 07033, USADepartment of Chemistry, Modeling and Informatics, Merck & Co., Inc., Kenilworth, NJ 07033, USADiscovery Biologics, Protein Sciences, Merck & Co., Inc., South San Francisco, CA 94080, USAWe report the novel crystal structure and characterization of symmetrical, homodimeric humanized heavy-chain-only antibodies or dimers (HC2s). HC2s were found to be significantly coexpressed and secreted along with mAbs from transient CHO HC/LC cotransfection, resulting in an unacceptable mAb developability attribute. Expression of full-length HC2s in the absence of LC followed by purification resulted in HC2s with high purity and thermal stability similar to conventional mAbs. The V<sub>H</sub> and C<sub>H</sub>1 portion of the heavy chain (or Fd) was also efficiently expressed and yielded a stable, covalent, and reducible dimer (Fd2). Mutagenesis of all heavy chain cysteines involved in disulfide bond formation revealed that Fd2 intermolecular disulfide formation was similar to Fabs and elucidated requirements for Fd2 folding and expression. For one HC2, we solved the crystal structure of the Fd2 domain to 2.9 Å, revealing a highly symmetrical homodimer that is structurally similar to Fabs and is mediated by conserved (C<sub>H</sub>1) and variable (V<sub>H</sub>) contacts with all CDRs positioned outward for target binding. Interfacial dimer contacts revealed by the crystal structure were mutated for two HC2s and were found to dramatically affect HC2 formation while maintaining mAb bioactivity, offering a potential means to modulate novel HC2 formation through engineering. These findings indicate that human heavy-chain dimers can be secreted efficiently in the absence of light chains, may show good physicochemical properties and stability, are structurally similar to Fabs, offer insights into their mechanism of formation, and may be amenable as a novel therapeutic modality.https://www.mdpi.com/2073-4468/9/4/66antibodyheavy-chain dimerheavy-chain antibodycrystal structure
collection DOAJ
language English
format Article
sources DOAJ
author Carl Mieczkowski
Soheila Bahmanjah
Yao Yu
Jeanne Baker
Gopalan Raghunathan
Daniela Tomazela
Mark Hsieh
Mark McCoy
Corey Strickland
Laurence Fayadat-Dilman
spellingShingle Carl Mieczkowski
Soheila Bahmanjah
Yao Yu
Jeanne Baker
Gopalan Raghunathan
Daniela Tomazela
Mark Hsieh
Mark McCoy
Corey Strickland
Laurence Fayadat-Dilman
Crystal Structure and Characterization of Human Heavy-Chain Only Antibodies Reveals a Novel, Stable Dimeric Structure Similar to Monoclonal Antibodies
Antibodies
antibody
heavy-chain dimer
heavy-chain antibody
crystal structure
author_facet Carl Mieczkowski
Soheila Bahmanjah
Yao Yu
Jeanne Baker
Gopalan Raghunathan
Daniela Tomazela
Mark Hsieh
Mark McCoy
Corey Strickland
Laurence Fayadat-Dilman
author_sort Carl Mieczkowski
title Crystal Structure and Characterization of Human Heavy-Chain Only Antibodies Reveals a Novel, Stable Dimeric Structure Similar to Monoclonal Antibodies
title_short Crystal Structure and Characterization of Human Heavy-Chain Only Antibodies Reveals a Novel, Stable Dimeric Structure Similar to Monoclonal Antibodies
title_full Crystal Structure and Characterization of Human Heavy-Chain Only Antibodies Reveals a Novel, Stable Dimeric Structure Similar to Monoclonal Antibodies
title_fullStr Crystal Structure and Characterization of Human Heavy-Chain Only Antibodies Reveals a Novel, Stable Dimeric Structure Similar to Monoclonal Antibodies
title_full_unstemmed Crystal Structure and Characterization of Human Heavy-Chain Only Antibodies Reveals a Novel, Stable Dimeric Structure Similar to Monoclonal Antibodies
title_sort crystal structure and characterization of human heavy-chain only antibodies reveals a novel, stable dimeric structure similar to monoclonal antibodies
publisher MDPI AG
series Antibodies
issn 2073-4468
publishDate 2020-11-01
description We report the novel crystal structure and characterization of symmetrical, homodimeric humanized heavy-chain-only antibodies or dimers (HC2s). HC2s were found to be significantly coexpressed and secreted along with mAbs from transient CHO HC/LC cotransfection, resulting in an unacceptable mAb developability attribute. Expression of full-length HC2s in the absence of LC followed by purification resulted in HC2s with high purity and thermal stability similar to conventional mAbs. The V<sub>H</sub> and C<sub>H</sub>1 portion of the heavy chain (or Fd) was also efficiently expressed and yielded a stable, covalent, and reducible dimer (Fd2). Mutagenesis of all heavy chain cysteines involved in disulfide bond formation revealed that Fd2 intermolecular disulfide formation was similar to Fabs and elucidated requirements for Fd2 folding and expression. For one HC2, we solved the crystal structure of the Fd2 domain to 2.9 Å, revealing a highly symmetrical homodimer that is structurally similar to Fabs and is mediated by conserved (C<sub>H</sub>1) and variable (V<sub>H</sub>) contacts with all CDRs positioned outward for target binding. Interfacial dimer contacts revealed by the crystal structure were mutated for two HC2s and were found to dramatically affect HC2 formation while maintaining mAb bioactivity, offering a potential means to modulate novel HC2 formation through engineering. These findings indicate that human heavy-chain dimers can be secreted efficiently in the absence of light chains, may show good physicochemical properties and stability, are structurally similar to Fabs, offer insights into their mechanism of formation, and may be amenable as a novel therapeutic modality.
topic antibody
heavy-chain dimer
heavy-chain antibody
crystal structure
url https://www.mdpi.com/2073-4468/9/4/66
work_keys_str_mv AT carlmieczkowski crystalstructureandcharacterizationofhumanheavychainonlyantibodiesrevealsanovelstabledimericstructuresimilartomonoclonalantibodies
AT soheilabahmanjah crystalstructureandcharacterizationofhumanheavychainonlyantibodiesrevealsanovelstabledimericstructuresimilartomonoclonalantibodies
AT yaoyu crystalstructureandcharacterizationofhumanheavychainonlyantibodiesrevealsanovelstabledimericstructuresimilartomonoclonalantibodies
AT jeannebaker crystalstructureandcharacterizationofhumanheavychainonlyantibodiesrevealsanovelstabledimericstructuresimilartomonoclonalantibodies
AT gopalanraghunathan crystalstructureandcharacterizationofhumanheavychainonlyantibodiesrevealsanovelstabledimericstructuresimilartomonoclonalantibodies
AT danielatomazela crystalstructureandcharacterizationofhumanheavychainonlyantibodiesrevealsanovelstabledimericstructuresimilartomonoclonalantibodies
AT markhsieh crystalstructureandcharacterizationofhumanheavychainonlyantibodiesrevealsanovelstabledimericstructuresimilartomonoclonalantibodies
AT markmccoy crystalstructureandcharacterizationofhumanheavychainonlyantibodiesrevealsanovelstabledimericstructuresimilartomonoclonalantibodies
AT coreystrickland crystalstructureandcharacterizationofhumanheavychainonlyantibodiesrevealsanovelstabledimericstructuresimilartomonoclonalantibodies
AT laurencefayadatdilman crystalstructureandcharacterizationofhumanheavychainonlyantibodiesrevealsanovelstabledimericstructuresimilartomonoclonalantibodies
_version_ 1724417487626305536